Your browser doesn't support javascript.
loading
Incidence of opioid-induced esophageal dysfunction.
Ladrón Abia, Pablo; Ortiz, Vicente; García-Campos, María; Saéz-González, Esteban; Mínguez Sabater, Alejandro; Izquierdo, Rosa; Garrigues, Vicente.
Affiliation
  • Ladrón Abia P; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: pablo.ladronabia@gmail.com.
  • Ortiz V; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • García-Campos M; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Saéz-González E; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Mínguez Sabater A; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Izquierdo R; Pain Unit, Anesthesiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Garrigues V; Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Department of Medicine, Universidad de Valencia, Valencia, Spain.
Gastroenterol Hepatol ; 46(4): 249-254, 2023 Apr.
Article in En, Es | MEDLINE | ID: mdl-35605820
ABSTRACT

BACKGROUND:

Retrospective studies have suggested that long-term use of opioids can cause esophageal motility dysfunction. A recent clinical entity known as opioid-induced esophageal dysfunction (OIED) has been postulated. There is no data from prospective studies assessing the incidence of opioid-induced effects on the esophagus.

AIM:

Evaluate the incidence of OIED during chronic opioid therapy.

METHODS:

From February 2017 to August 2018, all patients seen in the Pain Unit of the hospital, who started opioid treatment for chronic non-neoplastic pain and who did not present esophageal symptoms previously, were included. The presence of esophageal symptoms was assessed using the Eckardt score after 3 months and 1 year since the start of the study. In February 2021, the clinical records of all included patients were reviewed to assess whether esophageal symptoms were present and whether opioid therapy was continued. In patients presenting with esophageal symptoms, an endoscopy was performed and, if normal, a high-resolution esophageal manometry was performed. For a confidence level of 95%, a 4% margin of error and an estimated prevalence of 4%, a sample size of 92 patients was calculated.

RESULTS:

100 patients were included and followed while taking opioids, for a median of 31 months with a range between 4 and 48 months. Three women presented with dysphagia during the first 3 months of treatment, being diagnosed with esophagogastric junction outflow obstruction; type II and type III achalasia. The cumulative incidence of OIED was 3%; 95%-CI 0-6%.

CONCLUSIONS:

Chronic opioid therapy in patients with chronic non-neoplastic pain is associated with symptomatic esophageal dysfunction.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Motility Disorders / Esophageal Achalasia Type of study: Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: En / Es Journal: Gastroenterol Hepatol Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Motility Disorders / Esophageal Achalasia Type of study: Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: En / Es Journal: Gastroenterol Hepatol Year: 2023 Document type: Article